PE20080840A1 - Metodos para administrar agentes hipoglucemiantes de larga duracion - Google Patents

Metodos para administrar agentes hipoglucemiantes de larga duracion

Info

Publication number
PE20080840A1
PE20080840A1 PE2007001215A PE2007001215A PE20080840A1 PE 20080840 A1 PE20080840 A1 PE 20080840A1 PE 2007001215 A PE2007001215 A PE 2007001215A PE 2007001215 A PE2007001215 A PE 2007001215A PE 20080840 A1 PE20080840 A1 PE 20080840A1
Authority
PE
Peru
Prior art keywords
hypoglycemiant
lived
agents
methods
administering long
Prior art date
Application number
PE2007001215A
Other languages
English (en)
Inventor
Mark A Busch
Jessica E Matthews
Susan E Walker
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20080840A1 publication Critical patent/PE20080840A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN POLIPEPTIDO QUE TIENE POR LO MENOS UN AGONISTA GLP-1, EL CUAL PROPORCIONA UNA CONCENTRACION MAXIMA DE DICHO POLIPEPTIDO DE 0,6 Nm Y UN AREA BAJO LA CURVA DE 3,5 Nm x DIA APROXIMADAMENTE, DURANTE 1 SEMANA. EL AGONISTA DE GLP-1 ES LA HORMONA INCRETINA, COMO FRAGMENTO, CONJUGADO, VARIANTE O MIMETICO DE LA MISMA, LOS CUALES PUEDEN ESTAR FUSIONADOS O NO CON ALBUMINA. DICHO COMPUESTO ES UTIL COMO HIPOGLUCEMIANTE
PE2007001215A 2006-09-13 2007-09-11 Metodos para administrar agentes hipoglucemiantes de larga duracion PE20080840A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82547206P 2006-09-13 2006-09-13
US86839106P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
PE20080840A1 true PE20080840A1 (es) 2008-08-27

Family

ID=39184534

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001215A PE20080840A1 (es) 2006-09-13 2007-09-11 Metodos para administrar agentes hipoglucemiantes de larga duracion
PE2012001061A PE20121528A1 (es) 2006-09-13 2007-09-11 Metodos para administrar agentes hipoglucemiantes de larga duracion

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012001061A PE20121528A1 (es) 2006-09-13 2007-09-11 Metodos para administrar agentes hipoglucemiantes de larga duracion

Country Status (25)

Country Link
US (3) US8338369B2 (es)
EP (1) EP2073834B1 (es)
JP (2) JP5524620B2 (es)
KR (1) KR101472601B1 (es)
CN (1) CN103705911A (es)
AR (1) AR062775A1 (es)
AU (1) AU2007296499C1 (es)
BR (1) BRPI0716765A8 (es)
CA (1) CA2662622C (es)
CL (1) CL2007002634A1 (es)
CR (1) CR10684A (es)
EA (1) EA017159B1 (es)
ES (1) ES2442869T3 (es)
IL (1) IL197448A (es)
JO (1) JO2945B1 (es)
MA (1) MA30768B1 (es)
MX (1) MX2009002863A (es)
MY (1) MY149911A (es)
NO (1) NO20091266L (es)
NZ (1) NZ575419A (es)
PE (2) PE20080840A1 (es)
SG (2) SG174770A1 (es)
TW (1) TWI430806B (es)
WO (1) WO2008033888A2 (es)
ZA (1) ZA200901548B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029798T2 (en) 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
US8748377B2 (en) * 2008-12-10 2014-06-10 Glaxosmithkline Llc Pharmaceutical compositions
EP2566502A4 (en) * 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
JP5902194B2 (ja) 2010-12-16 2016-04-13 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
HRP20231060T1 (hr) 2012-03-22 2023-12-22 Novo Nordisk A/S Pripravci peptida glp-1 i njihova priprava
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
DK3004155T3 (da) 2013-05-28 2022-01-03 Takeda Pharmaceuticals Co Peptidforbindelse
CA3024962A1 (en) 2016-05-24 2017-11-30 Takeda Pharmaceutical Company Limited Peptide compound
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI837615B (zh) * 2021-03-23 2024-04-01 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
PT966297E (pt) 1996-08-08 2009-03-18 Amylin Pharmaceuticals Inc Regulação da motilidade gastrintestinal
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
CZ2001690A3 (cs) * 1998-08-28 2002-04-17 Eli Lilly And Company Způsob podávání inzulinotropních peptidů
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP1355942B1 (en) 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
AU2002239384B2 (en) 2000-12-13 2007-01-11 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
EP1542712A2 (en) * 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
CA2458371A1 (en) * 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
JP2005514337A (ja) 2001-10-18 2005-05-19 ブリストル−マイヤーズ　スクイブ　カンパニー ヒトグルカゴン様ペプチド−１模倣体、並びに糖尿病および関連疾患の処置におけるその使用
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005077042A2 (en) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
CA2468700A1 (en) * 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
PL1689757T3 (pl) * 2003-11-12 2015-05-29 Sino Med Int Alliance Inc Heterocykliczne związki kwasu boronowego
CN100577412C (zh) * 2004-01-13 2010-01-06 旭硝子株式会社 多层层合体
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
HUE029798T2 (en) * 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators

Also Published As

Publication number Publication date
SG174770A1 (en) 2011-10-28
CR10684A (es) 2009-04-28
JP5524620B2 (ja) 2014-06-18
KR101472601B1 (ko) 2014-12-15
CA2662622A1 (en) 2008-03-20
ES2442869T3 (es) 2014-02-14
AR062775A1 (es) 2008-12-03
US20100009910A1 (en) 2010-01-14
EP2073834A4 (en) 2010-11-03
CL2007002634A1 (es) 2008-05-16
IL197448A (en) 2013-06-27
EP2073834B1 (en) 2013-10-23
IL197448A0 (en) 2011-08-01
US20130005652A1 (en) 2013-01-03
MY149911A (en) 2013-10-31
AU2007296499C1 (en) 2013-09-12
TW200824706A (en) 2008-06-16
WO2008033888A2 (en) 2008-03-20
NZ575419A (en) 2011-11-25
JO2945B1 (en) 2016-03-15
KR20090059155A (ko) 2009-06-10
PE20121528A1 (es) 2012-12-12
TWI430806B (zh) 2014-03-21
EA200970274A1 (ru) 2009-08-28
US8338369B2 (en) 2012-12-25
JP2014148524A (ja) 2014-08-21
SG10201501749WA (en) 2015-05-28
MX2009002863A (es) 2009-03-30
EA017159B1 (ru) 2012-10-30
BRPI0716765A2 (pt) 2013-09-24
EP2073834A2 (en) 2009-07-01
BRPI0716765A8 (pt) 2017-02-21
JP2010503697A (ja) 2010-02-04
ZA200901548B (en) 2010-02-24
US20140066371A1 (en) 2014-03-06
AU2007296499B2 (en) 2013-05-02
AU2007296499A1 (en) 2008-03-20
CN103705911A (zh) 2014-04-09
MA30768B1 (fr) 2009-10-01
WO2008033888A3 (en) 2008-10-16
CA2662622C (en) 2017-01-17
JP5753924B2 (ja) 2015-07-22
NO20091266L (no) 2009-06-09

Similar Documents

Publication Publication Date Title
PE20080840A1 (es) Metodos para administrar agentes hipoglucemiantes de larga duracion
NI201200013A (es) Composición de insulina de acción prolongada
ES2528346T3 (es) Derivado de péptido insulinotrópico en el que se ha modificado su aminoácido N-terminal
MA32703B1 (fr) Combinaison d'une insuline et d'un agoniste de glp 1
PE20120514A1 (es) Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica
CO7200249A2 (es) Variantes de oxintomodulina de acción prolongada y métodos de producción de las mismas
AR065370A1 (es) Moduladores de htra1 - pdz y htra3 pdz
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
AR052082A1 (es) Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante el incremento de la concentracion sanguinea de gelp -1
CL2011003085A1 (es) Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes.
ECSP19062769A (es) Formulación de anticuerpo monoclonal anti-vrs
GT200500246A (es) Combinacion de compuestos organicos
PE20191143A1 (es) Nuevos compuestos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip
PE20211300A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
CL2010001146A1 (es) Proteina recombinante de circovirus porcino tipo 2 (pcv2); uso de la proteina recombinante para prevenir una infección por pcv2; un envase que comprende la composición inmunogénica (div exp 3475-2005).
ES2622444T3 (es) Actividad trombopoyética de polipéptidos tirosil-ARNt sintetasa
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
GT200600046A (es) Terapia de combinacion
CO5720212A1 (es) Composicion de anticuerpo her2
PE20150900A1 (es) Derivados de exendida-4 como agonistas duales de glp1/glucagon
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
AR077016A1 (es) Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
CO6612278A2 (es) Composición acuosa antitranspirante/desodorante
CL2011002761A1 (es) Compuestos derivados de heterociclos sustituidos, inhibidores del canal romk; composición farmacéutica; y su uso para provocar diuresis, natriuresis o ambas, hipertension, insuficiencia cardiaca, insuficiencia renal aguda y crónica y síndrome nefrótico, entre otras enfermedades.

Legal Events

Date Code Title Description
FC Refusal